

# Dr Hetal Shah, PhD

Subject Matter Expert – Medical Writing

710, Santorini Square,  
Lane Opp. Star Bazar,  
Satellite, Ahmedabad 380015.  
Gujarat, INDIA.  
+91 97277 16506

FOUNDER - DIRECTOR



[www.mewrit.com](http://www.mewrit.com)

[hetal@mewrit.com](mailto:hetal@mewrit.com)

[drhetalshah29@gmail.com](mailto:drhetalshah29@gmail.com)

[www.linkedin.com/in/drhetalshah](https://www.linkedin.com/in/drhetalshah)

Dr Hetal Shah is a **PhD Pharmacologist** and **Subject Matter Expert – Medical Writing** with **almost 22 years of first-hand experience** in the field of **clinical research and medical writing**. She is the **Founder of MeWriT® Healthcare Consulting** – an independent medical writing and training consultancy service based at Ahmedabad, India.

Gold medalist for her manifold academic achievements, **Dr Shah also has > 70 publications to her credit including book chapters, research papers, review articles and presentations at national as well as international forums**. As an SME with high standards for quality and work ethics, Dr Shah is extensively in developing integral regulatory documentation & publications for pharmaceuticals & research organizations.

A **trained clinical research professional**, she is well-versed with various national and international regulations governing clinical trials and good clinical practice. Dr Shah has a **rare combination of first-hand experience in handling varied clinical studies**, both, at investigative sites as well as CROs. She has in-depth knowledge of GCP and its implementation, clinical trial operations, trial monitoring as well as overall clinical project management. She serves as a **Pharmacologist and Clinical Expert** for various areas of clinical study design and protocol development, study reporting and regulatory responses.

As an **independent medical writing expert**, she takes full accountability for first-hand writing, editing and finalizing of submission-ready documents for various therapeutic areas. Her writing sphere currently ranges from preparation of **clinical trial documents to clinical study reports**; compilation of drug authorization dossiers to **scientific publications for journals**. Dr Shah is also an **experienced trainer** with practical approach to coaching, and independently conducts medical writing & Clinical Research workshops and trainings customized for various topics and audiences' needs. She is a member of the **International Society of Medical Publication Professionals (ISMPP)**, **Indian Society of Clinical Research (ISCR)**, executive committee of All India Medical Writers Association (AIMWA) and an ex-member of the DIA Medical Writing group of India.

An accomplished professional herself, she effectively collaborates with therapeutic area experts, biostatisticians, auditors, QA personnel, as well as in-house and allied clinical research teams to ensure a complete, accurate, cost-effective, and timely solution for your clinical projects or writing needs, with the best of quality and ethics.

On a personal front, Dr Shah is highly passionate about dance and fitness. She is a trained Bharatanatyam performer, has honed various Indian folk-dance forms and is currently pursuing her training in Kathak. She is yoga enthusiast with her eternal love for suryanamaskaras.

**Dr. Shah has been felicitated as 'Woman Entrepreneur in Pharma & Healthcare' by the AIC-LMCP foundation (supported by Atal Innovation Mission, Government of India) at Ahmedabad, on 12 January 2019.**

**Dr. Shah has received the 'Hall of Fame' Awards, thrice in a row, from the Indian Society of Clinical Research (ISCR) in 2021, 2022, and 2023 for her contributions to the Medical Writing Council activities.**

*A brief account of Dr Shah's Profile is mentioned below for a quick reference. Full detailed CV is also included further here.*

**Expert support for Scientific & Regulatory Documentation:** including clinical trial protocols and study designs, informed consent forms & other trial related documents, clinical study reports (ICH-E3 compliant), CTD modules, drug application dossiers, event narratives, ICMJE compliant scientific publications including original articles, scientific reviews, short communications, conference & educational materials, SOPs, and much more...

**Pharmacologist and Clinical Expert** support for study design aspects, reporting issues, independent expert reviewer for drug/device dossiers, regulatory responses and resolutions.

**Workshop Leader & Trainer** for various medical writing & clinical research needs.

**Clinical Research Support** for clinical study management and related activities.



## BRIEF Curriculum Vitae

---

**Name:** Dr Hetal Amit Shah  
**DOB:** 29 Feb 1980  
**Age:** 45 years  
**Gender:** Female

---

### Academics:

Academic Qualifications: PhD (Pharmacology); M. Pharm (Gold Medalist)

Language Proficiencies:

- English (IELTS: 7.5/9 bands; Writing – 8/9, Speaking-7.5/9)
- Gujarati, Hindi (Fluent)
- French (Introductory)

Publication Credentials: **50 odd** scientific presentations and publications

- 4 book chapters
- 5 original research articles
- 8 literature reviews
- 30 original research presentations at international/national scientific meetings

**Professional Acknowledgments:** Acknowledged for professional medical writing support in **25 scientific publications and presentations** in national and international journals and congresses.

---

### Professional Experience:

***Almost 22 years of consolidated professional experience in the field of Clinical Research & Medical Writing***

- **Clinical Research Project Management** – 9 years
  - Clinical site study manager – Investigative Site (via SMO): 2 years
  - Clinical research manager – SMO: 3 years
  - Regional team leader– CRO project management: 3 years
- Line Management – CRO: 5 years
- **Medical Writing** – 17 years
- **Independent Pharmacologist & Clinical Expert** – 17 years

### Experience in Medical Writing

- First-hand experience in drafting, reviewing and finalizing research documents across three major portfolios: **regulatory, publication and educational.**
- **Therapeutic area** experience including, but not limited to: ***oncology, cardiology and cardiovascular, autoimmune diseases, gastroenterology, metabolic disorders, diabetic, infectious diseases including COVID-17, orthopaedics, gynaecology, vaccines including COVID vaccines, medical devices and nutraceuticals.***
- Experienced primary writer/author for various **clinical trial documents** – protocols, IBs, CRFs, ICFs, other patient/study materials; CTD/drug submission dossiers; clinical study reports (ICH – E3 compliant); event narratives; **medical publications** including original research ***manuscripts, literature reviews, clinical case reports***, scientific abstracts, posters and presentations; scientific review and editing of documents; developing SOPs, and related.

- **Workshop Leader/Trainer** for various medical writing and clinical research topics including, but not limited to: clinical trials basics, good clinical practice, Ethics committee aspects, basics of medical writing including literature search, writing basics, ethics, biostatistics, reviewing; advanced training in publication writing, original and review articles, case reports, event narratives, CTD modules, clinical study designs, clinical study reports, and related. Workshops are customised and conducted based on the audience's need and interest.

### **Experience in Clinical Trial/Project Management (Clinical Operations)**

#### *Clinical Site Study Manager*

- End-to-end clinical study management at investigative site including site coordination, clinical study and patient management, CRF completions, overall trial conduct as site personnel; overlooking clinical site coordinators and collaboration with CROs and sponsors.

#### *Clinical Research Manager*

- Overall responsibility of clinical study planning, protocol discussions, regulatory and project management planning, drafting monitoring plan, coordination with sponsors, managing CRA teams and day-to-day activity, oversight for on-site as well as in-house monitoring, matrix-driven performance management, training of CRAs, ongoing support and SPOC for sponsors.

#### *Regional Team Leader*

- Regional team leader overlooking start-up of large phase III trials in India and Asia Pacific regions. Primarily involved with leading study start-up phase, collaboration with sponsors managers, participation in overall project management planning and discussions, primary approver for IP packet release and site hand-overs.

### **Experience in Clinical Pharmacologist / Expert**

#### *Clinical Study Design inputs*

- Study Design Discussion and Development with Clinical Team for all phases of clinical trials; finalization of study outlines/synopsis for medical writers.

#### *Independent Review of Clinical Study Reports*

- Review and Expert inputs for clinical study reports – all phases. Collaboration with medical writing team for revisions and finalization for CSR submissions.

#### *Responses to Regulatory Queries*

- Thorough & Independent Reviewer for Clinical regulatory queries. First-hand drafting and finalization of responses to Regulators in line of study results and available supporting documentations; with a strong and assertive presentation of responses.

#### *Pharmacologist*

- Serve as pharmacological experts for aspects of drug/device trial designs and reporting, and confirmation of compliance to regulatory requirements.

### **Experience in People Management**

#### *Line Management Experience*

- Handling direct line and in-direct functional reports, overlooking day-to-day activities, project planning, time management, team leadership and overall team building. Ensuring CRA trainings and ongoing support, overseeing KPIs, and matrix-driven performance appraisals.
- Managing extended teams of expert consultants – medical writers; therapeutic area experts, biostatisticians as part of team MeWriT.

---

**Current Professional Portfolio:**

---

***Independent Consultant – Pharmaceutical organizations & CROs***

- Medical Writing Expert
- Pharmacologist
- Clinical Research Advisor

***Founder & Director – MeWriT Healthcare Consulting***

Providing professional support across three major segments:

- **Medical Writing** for pharma regulatory documentation, scientific publications, drug dossiers, educational and related.
- **Workshops & Training** for various medical writing & clinical research aspects – customized to audience's interest.
- **Clinical research support** for clinical trials/project planning and management, sponsor collaboration and representation, team meetings and training, people management and related consultations.

Dr. Hetal Shah has been felicitated as '**Woman Entrepreneur in Pharma & Healthcare**' by the AIC-LMCP foundation (supported by Atal Innovation Mission, Government of India) at Ahmedabad, on 12 January 2019.

Dr. Shah has received the '**Hall of Fame**' Awards, thrice in a row, from the Indian Society of Clinical Research (ISCR) in 2021, 2022, and 2023 for her contributions to the Medical Writing Council activities.

---

## **FULL Curriculum Vitae**

BRIEF Curriculum Vitae .....	2
FULL Curriculum Vitae .....	5
1. PERSONAL.....	6
2. ACADEMICS.....	6
3. ACADEMIC CREDITS .....	6
4. SKILLS & TRAININGS .....	7
5. LICENSURE & MEMBERSHIPS .....	8
6. PROFESSIONAL STATISTICS.....	8
7. CURRENT PROFILE .....	9
8. PROFESSIONAL EXPERIENCE .....	10
8.1 <i>Principal Medical Writer &amp; Clinical Pharmacologist</i> .....	10
8.2 <i>Trainer &amp; Speaker for Medical Writing</i> .....	11
8.3 <i>Clinical Research Project Management</i> .....	14
8.4 <i>People Management</i> .....	16
9. PUBLICATIONS .....	17
9.1 Professional Acknowledgements .....	21

---

## 1. PERSONAL

---

Name: Dr Hetal Amit Shah  
DOB: 29 Feb 1980  
Age: 45 years  
Gender: Female

---

## 2. ACADEMICS

---

**PhD (Pharmacology)** : L M College of Pharmacy, Ahmedabad, India. April 2008  
Thesis Title: Evaluation of Drugs and Devices in patients with Acute Myocardial Infarction, Chronic Refractory Angina and Heart Failure

**M Pharm. (Pharmacology)** : L M College of Pharmacy, Ahmedabad, India. Sept 2003  
*[Gold Medalist]*

**B Pharm.** : L M College of Pharmacy, Ahmedabad, India. May 2001

---

## 3. ACADEMIC CREDITS

---

**Two Gold Medals** awarded at the Gujarat University, Ahmedabad for securing first position at M. Pharm level. Scored 75% at Gujarat University Examination of M Pharm-I in May 2002 and 73% in M Pharm-II and thus standing First in Gujarat University in M. Pharm Final semester (with specialization in Pharmacology).

Dissertation work submitted for the degree of M. Pharm at the Gujarat University consisted of the following subject: “Effect of combination of atorvastatin and fenofibrate in patients who have undergone Percutaneous Transluminal Coronary Angioplasty.”

Awarded the **Jindal Prize (Gold Medal & Certificate)** at the Indian Pharmacological society (IPS) - Gujarat Chapter meet on 1st Feb, 2004 for standing first in M. Pharm (Pharmacology) at Gujarat University by the IPS Ahmedabad Branch.

Obtained **First Position & Gold Medal** in “Advance Diploma in Community Pharmacy Management (ADCPM)” Program at Institute of Pharmaceutical Education and Research (IPER), Pune in August 2004.

Oral Presentation at the O. D. Gulati Prize session at the Annual conference of Indian Pharmacological Society, December 2003, New Delhi.

Presented Poster entitled “Pharmacoepidemiology and risk factors of Hypertension in Western Gujarat” in the Poster Session of Annual Conference of Indian Pharmacological Society, November 2002, Gwalior.

Nominated as **Young Investigator’s Awards Finalist** at the American College of Cardiology Conference ACC 2006 to be held in March 2006 at Atlanta, Georgia, US.

Participated in the annual conferences of Indian Pharmacological Society, Dec 2003, Nov 2002 and Jan 2002.

Participated in the annual meeting of the International Society of Heart Research (ISHR)-India section held at Chandigarh in Feb 2003.

Participated in the Joint International Conference of “International Society of Heart Research (ISHR)” and “International Academy of Cardiovascular Sciences (IACS)” Jan 2005 at Gandhinagar, Gujarat, India.

Participated in the European Society of Cardiology (ESC) Congress, 2005 held on 3 Sept – 7 Sept, 2005 at Stockholm, Sweden.

Participated in the 56th Annual Conference of the Cardiological Society of India on Dec 7-10, 2006 at Delhi, India.

---

## 4. SKILLS & TRAININGS

---

“**ICH-GCP training**” by Aventis pharmaceuticals Ltd in November 2003.

Certificate course on “**Overview of Clinical Research & Foundations in GCP**” by Academy of Clinical Excellence, Bombay college of Pharmacy in April 2006.

“Emerging Trends in Clinical Trials and Clinical Research: **Role of Clinicians and Pharmacologists**” conducted by L M College of Pharmacy, Ahmedabad and National Institute of Medical Sciences (India) in October 2007.

Certificate in “**General Course on Intellectual Property**” from WIPO Worldwide academy, June 2007.

‘Workshop on Scientific Paper Writing’- by Indian Pharmacological society Ahmedabad Branch in January 2007.

‘Medical Writing Workshop’- conducted by Dr Barry Drees (Ex-Director, EMWA), held by Prescription Pharma Support, Mumbai in March 2007.

“**ICH-GCP training**” by Quintiles Research Pvt Ltd, India. June 2008.

Online Training on “**Human Participants Protection Education for Research Teams**” – By National Institute of Health (NIH), USA.

Soft Skills trainings – Line Management related trainings at Quintiles 2008-2010.

Train-the-Trainer: Quintiles 2009.

Adept user of MS office applications, SPSS Statistical Software, Corel Draw, Adobe Photoshop and related.

Sound insights of medical/therapeutic areas, drug and research processes and related subject matters, both, by qualification as well as experience.

Comprehensive understanding of all applicable regulatory guidelines including ICH, FDA, EMA, CDSCO-DCGI, and excellent grasp over interpreting them effortlessly for ensuring her documents are up-to-date with the regulatory requirements. She goes an extra mile to keep herself in pace with any new or revised guidance.

A unique capability of liaising with all relevant stake holders including therapeutic experts, biostatisticians, data managers, project members, administrators and supporting team to ensure an accurate and complete deliverable on time!

---

## 5. LICENSURE & MEMBERSHIPS

---

### Life Member of Indian Society for Clinical Research

*Medical Writing – Council Member since 2019*

*Medical Writing – Council Co-Chair [Sep 2024-Mar2025]*

*Western Chapter – Governance Member since 2019*

### Life Member of Indian Pharmacological Society

Pharmacy Council of India: G-18516

Founder & Executive Committee member of *The All India Medical Writers Association (Obsolete)*

Ex-member of International Society of Medical Publication Professional (ISMPP)

Ex-member of Drug Information Association (DIA) & DIA MW India Group

---

## 6. PROFESSIONAL STATISTICS

---

Almost 22 years of consolidated experience as a Medical Writing and Clinical Research Professional.

- **Medical Writing:** Over 15 years of experience in Clinical and Regulatory writing.
- **Independent Pharmacologist & Clinical Expert** – 15 years
- **Clinical Research Project Management:** Over 9 years of experience on-site and in-house, SMO and CRO.
- **Line Management:** Over 5 years of experience in people management and team leadership.

Positions previously held:

- Sep 2003 to May 2008: VIBGYOR Scientific Research Pvt Ltd [now called CBCC Global] Ahmedabad, India.  
*Last position held:* Manager –Clinical Research & Medical Writing.  
*Roles:* Investigative site coordinator, site manager, study manager, clinical research manager, manager-medical writing, Expert Pharmacologist
- Jun 2008 to Jan 2012: Quintiles Research (India) Pvt Ltd. [now called IQVIA], Ahmedabad, India.  
*Last position held:* Manager – Site Startup.  
*Roles:* study team leader – India and Asia pacific, Team manager - India
- Part-time freelance medical writer – 2005 to 2012.
- Full-time Independent Consultant (Clinical Research & Medical Writing) since February 2012.
- Founded MeWriT in 2017.

---

## 7. CURRENT PROFILE

---

### Subject Matter Expert – Medical Writing

- Independent (Consultant) & Trainer – International & National Pharmaceutical Companies, Device Companies & CROs

Involved in various roles, as:

- Medical Writing Expert
- Clinical Pharmacologist

### Founder Director – MeWriT Consultancy, Ahmedabad, India.

MeWriT provides professional support across three major segments:

- **Medical Writing** for pharma regulatory documentation, scientific publications, drug dossiers, educational and related.
- **Workshops & Training** for various medical writing & clinical research aspects – customized to audience's interest.
- **Clinical Research Support** for clinical trials/project planning and management, sponsor collaboration and representation, team meetings and training, people management and related consultations.

**Dr. Shah has been felicitated as 'Woman Entrepreneur in Pharma & Healthcare' by the AIC-LMCP foundation (supported by Atal Innovation Mission, Government of India) at Ahmedabad, on 12 January 2019.**

**Dr. Shah has been received the 'Hall of Fame' Award from the Indian Society of Clinical Research (ISCR), thrice in a row, in 2021, 2022, and 2023 for her contributions to the Medical Writing Council activities.**

---

## 8. PROFESSIONAL EXPERIENCE

---

### 8.1 Principal Medical Writer & Clinical Pharmacologist

*Almost 22 years of neat first-hand experience as expert pharmacologist and clinical writing expert in compiling, organizing, writing, editing and preparing a wide range of submission-ready regulatory and research documentation; details as below:*

- Medical writing experience aligned to a broad range of therapeutic areas and therapies, including but not limited to: oncology, hematology, cardiovascular diseases, respiratory disease, endocrinology including diabetes, autoimmune diseases, nephrology and urology, infectious diseases, dermatology, gastroenterology, orthopaedics, women's health, neurosciences, biological therapies, anti-viral, antibiotics, herbals and nutraceuticals, homeopathic therapy, disinfectants and sterilizers, medical devices – diagnostic and therapeutic, immunology and vaccines.
- Drafted > **70 high-quality peer reviewed publications** across multiple therapeutic areas, eventually published in national and international journals, including research manuscripts, reviews, case reports, abstracts and posters for global congresses. *See 'Publications' above for more details.*
- Compiled close to **100 high quality essential documents** for all types of clinical studies including BA – BE, phase I to IV, post marketing surveillance studies and registries. These include investigators' brochures, protocols, consent documents, patient cards, paper case report forms.
- Special expertise in developing clinical study reports (CSRs) compliant to the ICH-E3 guidance, derived from experience with more than **50 CSRs** for various drug classes, vaccines, study phases and regulators.
  - *Principal Medical Writer for the landmark COVAXIN (Covid-19 vaccine) Trial in India.*
- Compilation of event narratives, experience of more than **5000 narratives**– specifically for serious/significant events and deaths compiled for CSRs and other regulatory purposes.
- Select experience compiling CTD modules – **over 50 clinical and non-clinical overviews and summaries**, for various categories of drugs/products and marketing authorizations viz. NDA, ANDA for the FDA; generics, bibliographic, hybrid and related for the EMA region compliant to the EU directives and NTA 2B guidelines, as well as for the Asian and emerging markets as per the ASEAN CTD guidelines.
- Understanding of pharmacovigilance related writing including the risk management plans (RMPs), development safety update reports (DSURs), periodic safety update reports (PSURs/PBRERs) and annual safety reports (ASRs).
- **Expert Support [as Pharmacologist and/or Clinical Reviewer]** in interpreting, drafting, revising and finalizing strong and assertive responses to regulatory queries (including FDA/EMA/MHRA/TGA, and alikes) in a systematic response format.
- **Expert Reviewer** for all medical writing deliverables across multiple clinical studies. A sharp eye-for-detail and performed high-end scientific reviews and editing/proof reading for various scientific and regulatory documents for in-house junior writers or extended sponsor teams.
- Educational communications including preparations of educational materials, slide kits, short communications, standard operating procedures, research grant writings, blog content, content for HCPs, and more.

**Credit of 50 odd Publications (as Author/Co-author) and 25 odd Professional Acknowledgements for Publications supported by MeWriT [for details see 'Publications'].**

---

## 8.2 *Trainer & Speaker for Medical Writing*

*Over 17 years as an adept workshop leader and trainer for various medical writing and clinical research topics of interest to the pharmaceutical and medical device corporates, clinical research organizations, students and academic institutes.*

- **Invited Expert** for the session on ‘Deciphering the ICMJE Guidance for writing your research paper’ for a virtual event organized by MedMarvels Medisage – for a PG Pharmacology Forum of 1900 odd MD students, held virtually on 11 Mar 2025.
- **Invited Speaker** on the topic of ‘Leveraging AI to Transform Data into Real-World Impact: Opportunities and Challenges’ at the DIA Workshop on ‘Journey of Clinical Trial Data from Regulatory Submissions to Real-world Application-Crafting Documents That Impact Clinical Practice’ organized by the DIA India group on 28 Feb 2025 at Mumbai.
- **Expert Speaker** for the topic of ‘Medical Writing in Pharma and Healthcare: Industry Perspective and Career Prospects’ organized at Indus Institute of Pharmacy and Research, Indus University, Ahmedabad on 11 Feb 2025.
- **Session chair** for the session on ‘Accelerating Submissions: Elevating the Role of Medical Writers’ at the Medical Writing track of the ISCR Annual Conference 2025, on 31 Jan 2025 at Mumbai.
- **Local Organizing Committee Member** and **Scientific Organizing Committee Member** for the 15<sup>th</sup> Annual Conference of the Indian Society for Clinical Research (ISCR), held on 31 Jan to 02 Feb 2025 at Mumbai.
- **Expert Speaker** at Anand Pharmacy College for the topic of ‘Overview of Medical Writing and Scientific Publications’ on 03 Jan 2025 at Anand, Gujarat.
- **Invited Expert and Panelist** at the event of ‘Work-Life Balance for Women’ organized by the Gujarat Technological University, Vidushi Gargi center for women development on 19 Oct 2024 at Ahmedabad.
- **Organizing team member** for the ‘MW Symposium 2024: Essentials, Advances and Opportunities’ organized by the ISCR MW council on 27 Sep 2024 at Bengaluru.
- **Emcee** for the ISCR and USFDA Workshop on ‘Conduct Matters: Regulatory Perspectives in the design and execution of BA/BE Studies for Generic Drugs’ organized at Ahmedabad on 16-17 Sep 2024.
- **Expert Speaker** at the Virtual Boot Camp organized by the ISCR Western Chapter on the topic of ‘Writing your research publications’ on 25 Jul 2024.
- **Speaker** at the Medical Writing Track for the ISCR Annual Conference held on 01-03 Feb 2024 at Hyderabad for the session on ‘‘Collaboration between CDM, Bios, and Medical Writing’ at the pre-conference workshop, and presentation on ‘Continued Professional Development for Medical Writers: One size doesnot fit all’ in the main conference.
- **Speaker** at the Scientific Writing Workshop organized by the Institute of Pharmacy, Nirma University on 06 Jan 2024, Ahmedabad, on the topic of ‘Essentials of Biomedical Publications’.
- **Workshop Leader** for ‘Medical Writing and Research Publications’ – 2-day program conducted by MeWriT for Tatvacare at Zydus wellness, Ahmedabad on 03-04 Nov 2023.
- **MeWriT OPEN HOUSE 2023**. Organized and executed this independent event. The event included 3 invited experts sessions: The spectrum of Medical Communications, Phase 1 Clinical trials, overview of PV documents. Open event under the aegis of MeWriT.

- **Emcee** for the Clinical Research Conclave 2023 organized by the Indian Society for Clinical Research (ISCR), on 07 Oct 2023 at Ahmedabad. **Panelist** for the discussion on ‘Changing Landscape of career prospects in clinical research with digitization and AI/ML - Skills for today v/s future Scenario’.
- **Workshop Leader** for ‘Original Research Publication Writing’ – a 1-day program for Novobliss Research, at Ahmedabad on 25 Aug 2023, conducted by MeWriT.
- **Workshop Leader** for ‘Scientific Writing Style’ – a 2-day program for Alceon MedTech Consulting, at Vadodara on 28 – 29 June 2023, conducted by MeWriT.
- **Workshop Leader** for ‘Essentials of Scientific Writing’ – a 1-day program for Cliantha Research, at Ahmedabad on 31 May 2023, conducted by MeWriT.
- **Workshop Leader** for ‘Clinical Study Reports’ – a 2-day program for Veeda Clinical Research, at Ahmedabad on 03-04 Apr 2023, conducted by MeWriT.
- **Faculty** at the Medical Writing Track for the ISCR Annual Conference held on 25 & 26 Feb 2023, Delhi. Speaker for the session on “Independent Medical Writing Providers: Finding Your Niche!”, and Panel Moderator for a discussion on ‘Cross-functional Collaboration: Challenges and Opportunities for Medical Writers (MW)’ at the conference.
- **Local Organizing Committee Member** for the 15<sup>th</sup> Annual Conference of the Indian Society for Clinical Research (ISCR), held virtually in Feb-Mar 2022.
- **Panelist** for the Discussion on ‘Freelancing in Medical Writing and Work-From-Home Opportunities in the New Changed Scenario’ at the ISCR Annual Conference on 11 Mar 2022 (virtual).
- **Workshop** for Medical Writing for Clinical Project Managers conducted virtually for a clinical research organization on 29 Nov 2021.
- **Keynote Speaker** at an international United Conference of WOMEN IN PHARMA held virtually on 15 Jul 2021.
- **Organizing Committee Member** at the ISCR Workshop on Clinical Study Protocols held virtually on 27 – 28 Aug 2021.
- **Workshop Leader** for ‘Medical Writing’ training conducted virtually on 22 Apr 2021 for a closed group of clinical experts of reproductive medicine from SRMC, Chennai.
- **Workshop Leader** for a Medical Writing Mini-workshop Series 2021 organized by MeWriT over January to May 2021.
- **Workshop Leader** for the pre-conference Medical Writing Workshop on ‘Effective Authoring of Clinical Study Reports in the Evolving Landscape of Data Transparency’ conducted as part of the annual conference of the Indian Society for Clinical Research (ISCR 2021), held virtually on 12 Mar 2021. Also delivered a session on ‘Critical Appraisal and Practical Implementation of CSR Guidances’ in this workshop.
- **Organizing Committee Member** at the annual conference of Indian Society for Clinical Research (ISCR 2021) held virtually on 19-20 Mar 2021.
- **Workshop Leader** for ‘Medical Writing’ training conducted virtually on 24 Oct 2020 for a closed group of Clinicians from Tata Memorial Hospital, Mumbai.
- **Panelist** for the discussion on ‘Clinical Trials - past, present and future’ at the international virtual conference on clinical research -INCRE2020 - organized by School of Bio Science and Technology, Vellore Institute of Technology on 03 Oct 2020.

- **Workshop Leader and Organizer** for a 2-day ONLINE program on ‘Essentials of Medical Writing’ for a corporate team of Medical Communications’ professionals from Pune on 20 & 21 June 2020.
- **Workshop Leader** for ‘Medical Writing’ training conducted on 11 Mar 2020 for a multinational pharma team – primarily non-writing audience – at Mumbai.
- **Speaker** at the annual conference of Indian Society for Clinical Research (ISCR 2020) on 24-25Jan, at Mumbai. Delivered a session on ‘Importance of Continuing Medical Education for Medical Writers’ in the form of Careers and Competencies in the Medical Writing Forum.
- **Workshop Faculty** at the national workshop for ‘Adopting the CORE reference for writing disclosure-friendly CSRs’, organized by the Indian Society for Clinical Research (ISCR) at Noida on 11 Nov 2019.
- **Workshop Faculty** at the national workshop of ‘Research Manuscript Writing’ organized by the Indian Society for Clinical Research (ISCR) at Ahmedabad on 18 & 19 Oct 2019.
- **Workshop Leader and Organizer** for a 2-day program on ‘Essentials of Scientific Writing Skills’ for a corporate team of Bioanalytical professionals at Bangalore on 24 & 25 Sep 2019.
- **Expert Faculty** for a scientific session on ‘Medical Writing – The Pharma and Healthcare Industry Perspective and Prospects’ for research scholars and students of Lovely Professional University (LPU), at Jalandhar, Punjab on 06 Sep 2019.
- **Workshop Leader** for ‘Medical Writing Workshop’ at Sri Jayadeva Institute of Cardiovascular Sciences, Bengaluru in association with IQVIA and Merck, conducted on 27 April 2019.
- **Expert Faculty** for a scientific session on ‘Medical Writing – The Pharma and Healthcare Industry Perspective and Prospects’ for faculties and students of Delhi Pharmaceutical Sciences and Research University (DPSRU) at Delhi on 14 February 2019.
- Served as an **expert industry panelist** for the discussion on ‘Startup and Investment Opportunities in Pharma and Healthcare’ at Alumni meet, L. M. College of Pharmacy, Ahmedabad on 12 January 2019.
- **Workshop Co-leader** for ‘External Medical Communications’ session at the 2-day National workshop on the ‘Essence of Medical Writing’ organized by the Indian Society of Clinical Research (ISCR) at Bangalore on 23-23 November 2018.
- **Workshop Leader** for ‘The art and science of publication writing’ workshop organized by CTQuest LLP., at Pune, India on 26 October 2018.
- **Workshop Leader** for ‘Medical Writing Workshop’ at Nepal Cancer Hospital, Kathmandu in association with IQVIA and Merck, conducted on 10 October 2018.
- **Workshop Leader** for ‘Medical Writing Workshop’ conducted for the Indira IVF Centre, Udaipur, Rajasthan in association with IQVIA and Merck, on 12 October 2018.
- **Workshop Faculty** at the ‘National Workshop on Scientific Writing’ organized by the SRM Medical College, Chennai in association with Medical Pharmacologist Society of India and ISCR on 09 Mar 2018.
- **Conference Resource Person** at the ‘Evidence Based Medicine and Clinical Research Conference’ organized by the SRM Medical College, Chennai in association with Medical Pharmacologist Society of India and ISCR on 10 Mar 2018.
- **Medical Writing Trainer** at Meril Life Sciences for ‘Medical Writing and Literature Search Training’ organized on campus on 13 Jan 2018.

- **Workshop leader** for ‘Medical Writing Workshop’ in June 2017 by Arkus Research Pvt Ltd., at Ahmedabad.
- **Visiting External Expert Faculty** for ‘Clinical Trials’ at Institute of Pharmacy, Nirma University, Ahmedabad, Mar – Jun 2016.
- **Workshop leader** for ‘Narrative Literature reviews’ conducted in December 2014 for BMS, Mumbai.
- **Conducted a web tutorial** on ‘Writing overviews: module 2.4 and 2.5 in the EU context’ for the Medical Writing working group, DIA India in June 2014.
- **Workshop facilitator and coordinator** for a two-day basic and advanced medical writing workshop, covering an array of medical writing aspects, held on 15-16 Nov 2013 by ISPE at AMA, Ahmedabad, with audience from academia as well as Industry.
- **Workshop leader** for ‘Poster Presentation’ Workshop conducted by All India Medical Writers’ Association at Bangalore in June 2008.

---

### **8.3 Clinical Research Project Management**

*Over 9 years of exhaustive experience on-site and in-house clinical (trials) project management at previous affiliations. Experienced in providing overall guidance and oversight for large multi-site, multi-protocol clinical projects in various roles viz. site coordinator, site manager, clinical research manager, clinical study manager, start-up team leader. Responsibilities undertaken as below:*

- Served as a Clinical research coordinator / site manager for investigative site and handled > 10 phase III/IV clinical studies
- Experienced in clinical trial monitoring at Indian sites & also supervised team of CRAs.
- For investigator-led/small scale studies, assumed overall responsibility for the preparation of protocols and Case Report Forms, finalization of monitoring and data management options (either in-house or contracted to a Contract Research Organization), ethics committee approval, development of recruitment strategies to increase patient randomization into the trial, the provision of clinical trial materials, and management of the trial.
- As a start-up team lead, participated in developing budget, timelines, quality guidelines, risk management planning, project strategic planning for start-up and execution, identification & selection of sites, regulatory submissions and approvals, project monitoring, overseeing startup CRA teams, conducting internal and external team meetings, & project handovers.
- Establish appropriate clinical tools and processes for the study team to support the execution of clinical deliverable and study timelines.
- Manage clinical study set-up and follow-up study activities through ongoing tracking and review of study progress. Report progress to appropriate clinical management and project management forums.
- Collaborate with other functional groups within the company such as data management, pharmacovigilance, and biostatistics where necessary to support milestone achievement and to manage study issues and obstacles.
- Track clinical budget consumption through regular review of project budget reports.
- Escalate out of scope requests to applicable higher line and implements corrective action wherever necessary to manager clinical costs.
- Establish customer service relationship with applicable client representative(s) through regular communications.

- Serve on clinical operations task forces and participate in department/corporate initiatives. Ensure adherence by project team to Standard Operating Procedures, Work Instructions, and Project Instructions.
- Serve as program lead, coordinate and establish consistent practices across all protocols which may include resourcing plans.
- Participate in sales presentation and proposal development; provide input into budget development.
- Participate in mentorship and training of more junior staff. Identify and record non-conformity with Company procedures, SOPs and internal QC program.
- Serve as a Regional and Global Lead which would include coordinating activities across regions.
- Ensure overall project efficiency and adherence to project timelines and financial goals.

---

## 8.4 People Management

*An entrepreneur with ongoing enriching experience in people management and team leadership. Experienced in handing direct and in-direct line reports at previous engagements, and has been involved with:*

- Ensuring the operational integration of departmental goals & objectives
  - Managing staff in accordance with organization's policies and applicable regulations.
  - Responsibilities including planning, assigning, and directing work; appraising performance and guiding professional development; rewarding and disciplining employees; addressing employee relations issues and resolving problems. Approve actions on human resources matters.
  - Participating in the selection and on boarding process for new staff by conducting candidate review and participating in the interviewing process. Conduct on boarding training for new staff in conjunction with human resources and training programs.
  - Accountability for staff efficiencies and adherence to SOPs, work instructions, and project instructions and timelines.
  - Participating in the allocation of resources to projects by assigning staff to projects that are appropriate to their experience and training.
  - Managing the quality of assigned staff's work through regular review and evaluation of work product.
  - Identifying quality risks and issues; and creating appropriate corrective action plans to prevent or correct deficiencies in performance of staff.
  - Ensuring that staff is meeting defined workload and quality metrics through regular review and reporting of findings as outlined by operations management.
  - Participated in operational quality or process initiatives.
  - Identifying and making recommendations to resolve ongoing training and development needs of the staff.
  - Monitoring KPIs, matrix-driven performance appraisals and team building
-

---

## 9. PUBLICATIONS

---

### *Book Chapters*

1. Shah HD, Parikh KH, Goyal RK. Recent Trends in Antiplatelet Therapy for Acute Coronary Syndromes: Glycoprotein IIb/IIIa receptor antagonists: In Pharmacotherapy of Heart Failure by S K Gupta 2005; 102:22.
2. Parikh KH, Shah HD. Stem Cell Therapy in ACS: Type, timing and promise: In The Post Graduate Medicine-2006.
3. Parikh KH, Shah HA. A Year in Percutaneous Interventions. In Cardiology Update 2006.
4. Goyal RK, Parikh KH, Shah HA. An Overview on the Management of Chronic Refractory Angina Pectoris. In Proceedings of International Symposium on RACS 2008: Pg 135-153.

### *Research Papers:*

5. Rozenman Y, Schwartz RS, Shah H, Parikh KH. Wireless acoustic communication with a miniature pressure sensor in the pulmonary artery for disease surveillance and therapy of patients with congestive heart failure. J Am Coll Cardiol 2007; 49: 784-9.  
<https://pubmed.ncbi.nlm.nih.gov/17306708/>
6. Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Shah KJ, Iyer S, Goyal RK. Beneficial Effects Of Addition Of Fenofibrate To Statin Therapy In Patients with Acute Coronary Syndrome After Percutaneous Coronary Interventions. Exp Clin Cardiol 2007, 12: 91-6.  
<https://europepmc.org/article/med/18650989>
7. Parikh KH, Chag MC, Shah KJ, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Shah HD, Goyal RK. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 2007; 85: 476-82.  
[https://www.researchgate.net/publication/6224504\\_Intracoronary\\_boluses\\_of\\_adenosine\\_and\\_sodium\\_nitroprusside\\_in\\_combination\\_reverses\\_slow\\_no-reflow\\_during\\_angioplasty\\_A\\_clinical\\_scenario\\_of\\_ischemic\\_preconditioning](https://www.researchgate.net/publication/6224504_Intracoronary_boluses_of_adenosine_and_sodium_nitroprusside_in_combination_reverses_slow_no-reflow_during_angioplasty_A_clinical_scenario_of_ischemic_preconditioning)
8. Parikh KH, Shah HA, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Goyal RK. Efficacy of PercuSurge in Acute myocardial Infarction patients undergoing Revascularization with a special emphasis on Procedural time. Ind Heart J 2008; 60: 101-9.  
[https://www.researchgate.net/publication/24011878\\_Efficacy\\_of\\_PercuSurge\\_in\\_acute\\_myocardial\\_infarction\\_patients\\_undergoing\\_revascularization\\_with\\_a\\_special\\_emphasis\\_on\\_procedural\\_time](https://www.researchgate.net/publication/24011878_Efficacy_of_PercuSurge_in_acute_myocardial_infarction_patients_undergoing_revascularization_with_a_special_emphasis_on_procedural_time)
9. Parikh KH, Shah HA, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Goyal RK, Rozenman Y, Hjalmarson A. Effect of Metoprolol CR/XL on Pulmonary Artery Pressure in Chronic Heart Failure Patients Assessed by an Implanted Ultrasonic Device with Special Emphasis on Diurnal Variation and Exercise Capacity. Ind Heart J 2009, 61(1).  
<https://pubmed.ncbi.nlm.nih.gov/19729686/>

### *Review Articles*

10. Goyal RK, Parikh KH, Shah HA. First-in-man Clinical Trials in India. CV Network Online 2007; 6(3): 46.

11. Parikh KH, Shah HA. Investigational Treatments and future directions in heart failure. *Cardiology Today* 2007; 12: 96-103.
12. Parikh KH, Tanna MT, Shah HA, Shah AR. Basics of Stem Cell Therapy in Heart Failure. *Cardiology Today* 2007; 12: 104-114.
13. Shah HD, Goyal RK. Nesiritide-A recombinant human BNP as a therapy for decompensated heart failure. *Ind J Pharmacol* 2005; 37: 196-7.  
<http://www.bioline.org.br/pdf?ph05052>
14. Shah HD, Goyal RK. Angiogenesis: A novel approach for future therapy. *Indian J Pharmac Edu* 2004;38(2).
15. Shah HD, Goyal RK. Glycoprotein IIb/IIIa receptor and its inhibition: A platelet directed therapeutic strategy. *Ind J Pharmacol* 2004; 36 (3): 133-9.  
<http://www.ijp-online.com/article.asp?issn=0253-7613;year=2004;volume=36;issue=3;spage=133;epage=139;aulast=Shah>
16. Shah HD. Novel Agents in Osteoporosis. *Ind J Pharmacol* 2004; 36 (1):48-9.  
<http://www.ijp-online.com/text.asp?2004/36/1/48/6801>
17. Shah HD, Goyal RK. Novel anti-obesity agents. *Ind J Pharmacol* 2002;34(5):372 - 3.  
<http://www.ijp-online.com/article.asp?issn=0253-7613;year=2002;volume=34;issue=5;spage=372;epage=373;aulast=Goyal;type=0>

#### *Abstracts & Presentations @ Scientific Conferences*

18. Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah HD, Goyal RK. Beneficial Effects Of Distal Protection Device In Reducing The Use Of Intracoronary Vasodilators And Glycoprotein IIb/IIIa Receptor Antagonists During Percutaneous Coronary Interventions. Poster Presentation at Annual Conference of Society of Cardiovascular Angiography and Interventions (SCAI), San Diego, May 2004. *Catheter Cardiovasc Interven* 2004; 62: pg 90.
19. Parikh KH, Shah HD, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Goyal RK. Revascularization In Acute Myocardial Infarction Using Percutaneous Distal Protection (RAPID). Poster Presentation at Annual Conference of Society of Cardiovascular Angiography and Interventions (SCAI), San Diego, May 2004. *Catheter Cardiovasc Interven* 2004; 62: pg 116.
20. Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah HD, Goyal RK. Improvement In MACE By Sequential Administration Of Boluses Of Intracoronary Adenosine And Sodium Nitroprusside During Percutaneous Coronary Interventions. Poster Presentation at Annual Conference of Society of Cardiovascular Angiography and Interventions (SCAI), San Diego, May 2004. *Catheter Cardiovasc Interven* 2004; 62: pg 130-131.
21. Shah HD, Iyer S, Shah K, Parikh K, Chag M, Shah U, Baxi H, Chandarana A, Naik A, Goyal RK. Effect of Statins in combination with fenofibrate in patients after percutaneous transluminal coronary angioplasty. *Ind J Pharmacol* 2004; 36(2): pg 113.
22. Shah H, Iyer S, Mehta K, Parikh K, Jain A, Goyal RK. Pharmaco-epidemiology and risk factors of Hypertension in western Gujarat. *Ind J Pharmacol* 2003;35(4), pg. 277.
23. Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Patel GT, Mathan G, Shah JN, Goyal RK. Association of White Blood cell count with the occurrence of slow/no reflow in acute coronary syndrome patients undergoing PCI. Poster presentation at Joint International Conference of ISHR and IACS, Jan 2005, Gujarat, India.

24. Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Patel GT, Mathan G, Shah JN, Goyal RK. Efficacy of PercuSurge Guardwire system in acute myocardial patients undergoing Primary / rescue PCI. Oral presentation at Joint International Conference of ISHR and IACS, Jan 2005, Gujarat, India.
25. Parikh KH, Shah HD, Chag MC, Shah UG, et al. Improvement In Mace By Sequential Administration Of Boluses Of Intracoronary Adenosine And Sodium Nitroprusside During Percutaneous Coronary Interventions. (Poster Presentation at Annual Congress) European Society of Cardiology, 2004, Munich, Germany.
26. Chag MC, Shah HD, Joshi MV, Parikh KH, Shah UG, et al. Renal artery stenting is safe and effective modality of treatment on Mid Term Follow Up. Poster Presentation at 56th Annual Conference of The Cardiological Society of India (CSI) at Bangalore, December 2004.
27. Chag MC, Parikh KH, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Shah HD, Shah KJ, Goyal RK. Increased Lipoprotein(a) as a strong risk factor for Coronary artery disease and the effect of Niacin amongst Indians. Oral Presentation at 56th Annual Conference of The Cardiological Society of India (CSI) at Bangalore, December 2004.
28. Shah HD, Goyal RK, Parikh KH. Intracoronary Boluses Of Adenosine And Sodium Nitroprusside Combination Reverses Slow/No Reflow During Angioplasty: A Clinical Scenario of Experimental Preconditioning. Oral and Poster presentation at the Young Investigator's Awards competition, American College of Cardiology Conference, March 2006.
29. Parikh KH, Shah HD, et al. First in Man:PAPIRUS – Monitoring Pulmonary artery Pressure by Implantable device Responding to Ultrasonic Signals. Oral presentation at the Late breaking Clinical trials session at ACC-i2 summit, American College of Cardiology Conference, March 2006.
30. Parikh KH, Shah HD, et al. First in Human Implanted Device in Pulmonary Artery Using Acoustic Telemetry Based On Non-Invasive Ultrasound Activation and Communication American College of Cardiology Conference, March 2006 (e Poster Presentation).
31. Parikh KH, Shah HD, et al. Effect Of Metoprolol XL on Pulmonary Artery Pressure In Patients With Heart Failure Measured Using First In Human Implantable Device Responding To Ultrasonic Signal. American College of Cardiology Conference, March 2006 (Poster Presentation). J Am Coll Cardiol 2006; 47: 310A.
32. Parikh KH, Shah HD, et al. Effect Of Metoprolol XL On Diurnal Variation In Pulmonary Artery Pressure Measured Non-invasively Using First In Human Implant Responding To Ultrasonic Signals. American College of Cardiology Conference, March 2006 (Poster Presentation). J Am Coll Cardiol 2006; 47: 370A.
33. Banai S, Keren G, Sievert H, Seth A, Ben Muvhar S, Naik AM, Medina A, Chandra P, Shah H, Parikh KH. First in Man: Coronary Sinus Narrowing with a Reducer Stent – A Possible Alternative Percutaneous Treatment for Patients with Refractory Angina. American College of Cardiology Conference, March 2006 (Poster Presentation). J Am Coll Cardiol; 47: 17B.
34. Parikh K, Shah HA, Naik AM, Baxi HB, Chag MC, Chandarana AH, Hjalmarson A, Rozenman Y. First in man: measurement of diurnal variation in pulmonary artery systolic and diastolic pressure in heart failure patients using an innovative implantable device responding to ultrasonic signals. Presented at Annual conference of European Society of Cardiology- World Congress of Cardiology, September 2006, Spain (Poster Presentation). Eur Heart J 2006; 27 (Abstract Supplement): 485.
35. Parikh K, Shah HA, Naik AM, Baxi HB, Chag MC, Chandarana AH, Hjalmarson A, Rozenman Y. First in Man: non-invasive measurement of variation in pulmonary artery pressure following exercise in heart failure patients using an innovative implantable device involving acoustic telemetry. Presented at Annual conference of European Society of Cardiology-World Congress of

- Cardiology, September 2006, Spain (Poster Presentation) Eur Heart J 2006; 27 (Abstract Supplement): 949.
36. Parikh K, Shah HA, Naik AM, Baxi HB, Chag MC, Chandarana AH, Hjalmarson A, Rozenman Y. First in man: effect of metoprolol CR/XL on exercise capacity and subsequent variation in Pulmonary Artery Pressure in Heart Failure patients using an innovative implant involving acoustic telemetry. Presented at Annual conference of European Society of Cardiology-World Congress of Cardiology, September 2006, Spain (Poster Presentation) Eur Heart J 2006; 27 (Abstract Supplement): 949.
  37. Parikh K, Shah HA, Naik AM, Baxi HB, Chag MC, Chandarana AH, Hjalmarson A, Rozenman Y. First in man non-invasive monitoring of pulmonary artery pressure from an implantable device using acoustic telemetry: a one-year follow-up data. Presented at Annual conference of European Society of Cardiology-World Congress of Cardiology, September 2006, Spain (Poster Presentation) Eur Heart J 2006; 27 (Abstract Supplement): 202.
  38. Chag MC, Shah HA, Naik AM, et al. First-In-Man: comparison of ImPressure device measuring pulmonary artery pressure non-invasively with conventional contrast echocardiography In Congestive Heart Failure. Presented at Annual conference of European Society of Cardiology-World Congress of Cardiology, September 2006, Spain (Poster Presentation). Eur Heart J 2006; 27 (Abstract Supplement): 202.
  39. Shah H, Goyal RK, Naik AM, Baxi HA, Chag MC, Hjalmarson A, Rozenman Y, Parikh KH. First in Man study: effect of Metoprolol CR/XL on diurnal variation in pulmonary artery pressure assessed non-invasively using an innovative implantable device responding to ultrasonic signals. Presented at Annual conference of European Society of Cardiology- World Congress of Cardiology, September 2006, Spain (Poster Presentation) Eur Heart J 2006; 27 (Abstract Supplement): 344.
  40. Parikh KH, Naik AM, Shah HA, Chandarana AH, Chag MC, Shah UG, Baxi HA, Shah JN, Medina A, Bania S. First-in Man: Direct Comparison of Conventional Coronary Sinus Angiography And CT Angiography For Visualization And Sizing Of Coronary Sinus. Presented at 18th annual International Symposium of Transcatheter Cardiovascular Therapeutics (TCT) 2006, Washington, DC (ePoster).
  41. Parikh KH, Shah HA, Chandarana AH, Naik AM, Chag MC, Shah UG, Baxi HA, Shah JN, Medina A, Bania S. First-in Man: MultiSlice CT Angiography Visualization Of An Innovative First-in-man Coronary Sinus Reducer Stent In Patients With Refractory Angina. Presented at 18th annual International Symposium of Transcatheter Cardiovascular Therapeutics (TCT) 2006, Washington, DC (ePoster).
  42. HA Shah, JN Shah, AH Chandarana, MC Chag, UG Shah, HA Baxi, AM Naik, KH Parikh, RK Goyal. Association between the White Blood Cell Count and Occurrence of Slow or No Reflow Phenomenon in Patients with Acute Coronary Syndromes in the coronary Interventional Era. Accepted at Annual Conference of The Cardiological Society of India (CSI-2006). Ind Heart J 2006; 58: 436.
  43. HA Shah, MC Chag, MP Tanna, UG Shah, HA Baxi, et al. Incidences and Clinical Characteristics of No Reflow after Percutaneous Coronary Interventions in High Risk Asian Indian Patients. Presented at Annual Conference of The Cardiological Society of India (CSI- 2006). Ind Heart J 2006; 58: 418.
  44. KH Parikh, HA Shah, UG Shah, HA Baxi, AH Chandarana, et al. Initial Clinical experience with Bivalirudin as an anticoagulant during percutaneous coronary interventions in Asian Indian patients. Presented at Annual Conference of The Cardiological Society of India (CSI-2006). Ind Heart J 2006; 58: 435-6.
  45. KH Parikh, HA Shah, JN Shah, UG Shah, HA Baxi, AH Chandarana, AM Naik, RK Goyal, MC Chag Prospective randomized study of PercuSurge in Acute Myocardial Infarction Patients

- undergoing Revascularization with a special Emphasis on Procedural Time: A Two Year Follow-up. Presented at Annual Conference of The Cardiological Society of India (CSI-2006). Ind Heart J 2006; 58: 417-8.
46. Chandarana AH, Shah JN, Shah HA, Shah UG, Baxi HA, Naik AM, Joshi M, Goyal RK, Parikh KH, Chag MC. High Prevalence Of Renal Artery Stenosis In Hypertensive Patients With Triple Vessel Coronary Artery Disease: Recommendation For Simultaneous Renal Arteriogram For Earlier Intervention. Presented at Annual Conference of The Cardiological Society of India (CSI-2006). Ind Heart J 2006; 58:454.
47. Shah HA, Naik AM, Baxi HA, Chag MC, Shah UG, Chandarana AH, Goyal RK, Rozenman Y, Parikh KH. First-in-man: effect of Metoprolol CR/XL uptitration on pulmonary artery pressure and its variation in chronic heart failure monitored non-invasively by an implanted device using ultrasonic signals. Accepted for Oral Presentation at European Society of Cardiology Congress, September 2007 – Austria.

---

## 9.1 Professional Acknowledgements

---

1. Maharaj N, Uppada DR, Reddy N, Reddy P, Batalov A, Lvanova D, Staykova N, Baranauskaite A, Hassan LA. Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL\_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study. Arthritis Res Ther. 2024 Dec 21;26(1):225. <https://pubmed.ncbi.nlm.nih.gov/39709462/>

**Acknowledgements:** The authors thank Dr. Hetal Shah from MeWriT Healthcare Consulting, Ahmedabad, India for providing medical writing support in the development of this manuscript.

2. Chodankar, Deepa; Raval, Tapan K.1; Jeyaraj, Jeyaseelan2. The role of remote data capture, wearables, and digital biomarkers in decentralized clinical trials. Perspectives in Clinical Research 15(1):p 38-41, Jan–Mar 2024. | DOI: 10.4103/picr.picr\_219\_22. [Perspectives in Clinical Research](#)

**Acknowledgements:** We acknowledge the medical writing support provided by Utpala Daftary in revising and finalizing this manuscript. We thank Anushila Vaishali (MW Council Chair) and Dr. Hetal Shah (MW Council Member) for their efforts in the overall planning and execution of the publication activities for the DCT Position Paper initiative.

3. Sharma P, Bhowmick S, Nayak K, Bhattacharjee S, Lahiry S. Home nursing in clinical trials: Result from semi-structured qualitative interviews. Perspectives in Clinical Research (10.4103/picr.picr\_218\_22, December 06, 2023. [Perspectives in Clinical Research](#)

**Acknowledgements:** We acknowledge the medical writing support provided by Subhajit Hazra (ISCR member) in revising and finalizing this manuscript. We thank Anushila Vaishali (MW Council Chair) and Dr. Hetal Shah (MW Council Member) for their efforts in the overall planning and execution of the publication activities for the DCT Position Paper initiative.

4. Gupta A, Bhalla AK, Malik M, Gupta A, Bhargava V, Tiwari V, Gaur L, Gupta P, Jain M, Rana DS. Anti-T-Lymphocyte Immunoglobulin (Grafalon) as an Induction Agent for Renal Transplantation: A Real-World, Retrospective, Single-Center Experience. Exp Clin Transplant. 2022 May;20(5):480-486. <https://pubmed.ncbi.nlm.nih.gov/35620891/>

**Acknowledgements:** The authors thank Dr. Hetal Shah, MeWriT Healthcare Consulting, Ahmedabad, India, for her professional medical writing support in developing this manuscript and for styling it per journal requirements.

5. Indian Consensus Statement on the Evaluation and Management of Insomnia Disorders. A joint initiative by Association of Physicians of India (API) and Indian Society for Sleep Research (ISSR). Released at the APICON 2022, 14 – 17 April, 2022 at Jaipur.

**Acknowledgements:** *The Consensus Task Force would like to acknowledge the medical writing efforts of Dr. Hetal Shah, and ProAdWise Communications for their support in the development, revision, and publishing of this content.*

6. DCT POSITION PAPER. Decentralized Clinical Trials (DCT) – A Landscape Assessment with Recommendations for Growing the Ecosystem by Indian Society for Clinical Research (ISCR) 2022. [Internet]. Released on 04 Mar 2022 at the 15<sup>th</sup> Annual Conference of the Indian Society for Clinical Research (held Virtually). Available from: [https://www.iscr.org/files/Article/1317861265\\_ISCR-DCT-Position-Paper-\[Fina.pdf](https://www.iscr.org/files/Article/1317861265_ISCR-DCT-Position-Paper-[Fina.pdf)

**Acknowledgements:** *We thank the ISCR Medical Writing Council – Anushila Vaishali (MW Council Chair) and Dr. Hetal Shah (MW Council Member) for their efforts in planning and execution of the publication activity for the DCT initiative; and contributing as principal medical writers in the development of this position paper content...*

7. Bhattacharya A, Patra S, Banerjee S. Prevalence of Cardiovascular Risk Factors among Executive and Nonexecutive Workers in an Urban Public Sector Office Setting: A Cross-Sectional Epidemiological Study from Eastern India. *Indian J Community Med.* 2021 Oct-Dec;46(4):723-726. <https://pubmed.ncbi.nlm.nih.gov/35068743/>

**Acknowledgements:** *The authors would like to acknowledge the .....and the editorial support provided by MeWriT Healthcare Consulting, Ahmedabad, India, in the revision and styling of this manuscript as per journal requirements.*

8. Majumdar S, Chatterjee A, Banerjee S. A patient with atrioventricular block and ventricular tachycardia: think sarcoid! *J R Coll Physicians Edinb.* 2020 Sep;50(3):284-286. <https://pubmed.ncbi.nlm.nih.gov/32936104/>

**Acknowledgements:** *The authors would like to acknowledge the medical writing support provided by Dr. Hetal Shah, MeWriT™ from Ahmedabad, India for her professional support in revising the write-up, and styling the report as per the journal's requirements*

9. Chopra A, Mitra D, Agarwal R, Saraswat N, Chemburkar P, Sharma L. Real-life efficacy and safety of biosimilar adalimumab (ZRC-3197) in patients with plaque psoriasis: A tertiary care center experience. *Indian Dermatol Online J* 2020;11:182-6. <http://www.idoj.in/article.asp?issn=2229-5178;year=2020;volume=11;issue=2;spage=182;epage=186;aulast=Chopra>

**Acknowledgements:** *The authors acknowledge the contribution of Dr Hetal Shah, Principal Consultant, MeWriT™ from Ahmedabad, India, for her medical writing and editing support in the development and revision of this manuscript.*

10. Suvro B, Majumdar S, Konar A. Prevalence of atrial high-rate episodes and the risk factors in Indian patients with cardiac implantable electronic devices: Real-world data. *Journal of Arrhythmia.* 2019;00:1–6. <https://onlinelibrary.wiley.com/doi/full/10.1002/joa3.12239>

**Acknowledgements:** *The authors thank Dr Hetal Shah, PhD, Principal Medical Writing Consultant from MeWriT™, Ahmedabad, India for providing her professional support in preparation and revision of this manuscript.*

11. Kapoor S, Kaushik VV, Jain R, Rao V, Gharia M. Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data. *ACR Open Rheumatol.* 2019; 1(8): 480-4. <https://doi.org/10.1002/acr2.11067>

**Acknowledgements:** *The authors would also like to acknowledge the medical writing and editorial support provided by Dr. Hetal Shah, Founder & Principal Consultant, MeWriT™ from Ahmedabad, India, in the preparation and revision of this manuscript in collaboration with all the authors and reviewers, and in styling the article as per journal requirements. Medical Writing Support was outsourced to Dr. Hetal Shah, Founder and Principal Consultant of MeWriT (Ahmedabad, India).*

12. Kapoor S, Kaushik VV, Jain R, Rao V, Gharia M. Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data. *Rheumatol Ther.* 2019; 6(3): 451-459. <https://link.springer.com/article/10.1007/s40744-019-0166-2>

**Acknowledgements:** *The authors would like to acknowledge the medical writing and editorial support provided by Dr. Hetal Shah, Founder & Principal Consultant of MeWriT™, from Ahmedabad, India, in the preparation of this manuscript in collaboration with all the authors and reviewers, and in revising and styling the article as per journal requirements.*

13. Anupama Ramkumar. The New Pharmacovigilance Guidance In India- Diluted Wine In A Borrowed Bottle. Scientific Poster presentation at the 18<sup>th</sup> annual meeting of the International Society of Pharmacovigilance (ISoP) held on 11-14 November 2018 at Geneva, Switzerland.

**Acknowledgements:** *We thank Dr. Hetal Shah, PhD, our Medical Writing Consultant for her support in design and layout of this poster.*

14. Jha AB, Panchal SS, Shah A. Ellagic acid: Insights into its neuroprotective and cognitive enhancement effects in sporadic Alzheimer's disease. *Pharmacol Biochem Behav.* 2018 Dec;175:33-46. <https://pubmed.ncbi.nlm.nih.gov/30171934/>

**Acknowledgements:** *Authors would like to thank Dr. Hetal Shah, Principal Medical Writing Consultant at MeWriT Consultancy, India, for her professional editing services for this paper.*

15. Patil S. Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa. *Indian J Dermatol Venereol Leprol.* 2018 Nov-Dec;84(6):745-747. <http://www.ijdv.com/article.asp?issn=0378-6323;year=2018;volume=84;issue=6;spage=745;epage=747;aulast=Patil>

**Acknowledgements:** *The author would like to thank Dr. Hetal Shah, Independent Medical Writing Consultant from Ahmedabad, India for her professional support in drafting and revising this paper.*

16. Bandyopadhyay S, et al. Comparison of efficacy of biosimilar adalimumab therapy in ankylosing spondylitis patients – 6 months vs 1 year. Scientific Poster Presentation at IRACON 2017. Abstract published in *Ind J Rheumatol.* 2017. S16. <http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2017;volume=12;issue=5;spage=16;epage=132;aulast=>

**Acknowledgements:** *The authors would like to thank Dr. Hetal Shah, Independent Medical Writing Expert from Ahmedabad, India for her professional support in data analysis and abstract writing.*

17. Bandyopadhyay S. Comparison of efficacy of biosimilar adalimumab therapy in ankylosing spondylitis patients – 6 months vs 1 year. ABS124. Scientific Poster Presentation at the 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017) on 16 - 20 October 2017; Dubai, U.A.E.

**Acknowledgements:** *We thank Dr Hetal Shah, Independent Consultant-Medical Writing from Ahmedabad, India for her professional support in the content development and design of this scientific poster.*

18. Rao VKR. Improvement in disease activity and functional disability following treatment with biosimilar adalimumab in patients with ankylosing spondylitis. Scientific Poster Presentation. Presented at the 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017) on 16 - 20 October 2017; Dubai, U.A.E.

**Acknowledgements:** *We thank Dr Hetal Shah, Independent Consultant-Medical Writing from Ahmedabad, India for her professional support in the content development and design of this scientific poster.*

19. Badika A. Real-life patient characteristics and treatment assessments following clinical use of biosimilar adalimumab (Exemptia™) in patients with various inflammatory arthritis conditions.

ABS356. Scientific Poster Presentation at the 19th Asia Pacific League of Associations for Rheumatology Congress (APLAR 2017) on 16 - 20 October 2017; Dubai, U.A.E.

***Acknowledgements:** We thank Dr Hetal Shah, Independent Consultant-Medical Writing from Ahmedabad, India for her professional support in the content development and design of this scientific poster.*

20. V Kaushik, S Apparao. Real-life safety profile of biosimilar adalimumab in patients with inflammatory arthritic conditions. POSTER presentation at the Annual European Congress of Rheumatology; 14-17 Jun 2016; Madrid, Spain.

***Acknowledgements:** We thank Dr Hetal Shah, Independent Medical Writing Consultant from Ahmedabad, India for her professional support in preparation of this scientific poster.*

21. Dr. Syamasis Bandyopadhyay, Dr. Subhasis Dash, Dr. Abhrajit Ray, Dr. R. N. Sarkar. Efficacy and safety of adalimumab biosimilar (Exemptia) in Ankylosing spondylitis – POSTER presentation at the 18<sup>th</sup> Asia Pacific League of Associations for Rheumatology Congress (APLAR 2016); 26-29 Sep 2016; Shanghai, China.

***Acknowledgements:** We thank Dr Hetal Shah, Independent Medical Writing Consultant from Ahmedabad, India for her professional support in preparation of this scientific poster.*

22. Mathew AJ, Ganapati A, Kumar T S, Goel R, Sandhya P, Danda D. Real-life Safety Profile of ZRC3197 (Adalimumab Biosimilar) in Indian Patients with Common Rheumatic Diseases. Supplement of J Assoc Physicians India. 2017 May;65:30-2. <https://www.japi.org/r2a4c4c4/real-life-safety-profile-of-zrc3197-adalimumab-biosimilar-in-indian-patients-with-common-rheumatic-diseases>

***Acknowledgements:** We thank Dr Hetal Shah, Consultant Medical Writing Expert, from Ahmedabad, India, for her expert comments on this manuscript.*

23. Kapoor S. Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthritis: A Prospective Evaluation from Real-Life Clinical Practice. Supplement of J Assoc Physicians India. 2017 May;65:26-9. <https://www.japi.org/r2a4c4a4/switching-from-other-biologics-to-zrc3197-adalimumab-biosimilar-in-patients-with-spondyloarthritis-a-prospective-evaluation-from-real-life-clinical-practice>

***Acknowledgements:** We thank Dr Hetal Shah, Consultant Medical Writing Expert from Ahmedabad, India, for her professional service in drafting this paper.*

24. Bhati M, Bandyopadhyay S. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2016 Aug;35(8):1931-5. <https://link.springer.com/article/10.1007/s10067-016-3332-8>

***Acknowledgments:** We thank Dr Hetal Shah from Arkus Research Pvt. 294 Ltd., Ahmedabad, India, for her professional support in drafting this manuscript.*

25. Sharma B. Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis: A Real-life Experience. Supplement of J Assoc Physicians India. 2017 May;65:22-5. <https://www.japi.org/r274a444/clinical-use-of-zrc3197-adalimumab-biosimilar-in-patients-with-inflammatory-arthritis-a-real-life-experience>

***Acknowledgements:** We thank Dr Hetal Shah, Consultant Medical Writing Expert from Ahmedabad, India, for her professional service in drafting this manuscript.*

-----